TheraRadar
← Back
Data updated: Jun 28, 2026

TEYRO LABS

Generics

TEYRO LABS is a generic drug manufacturer focused on Oncology, Gastroenterology.

2007
Since
4
Drugs
-
Trials
0
New Drugs (2yr)

TEYRO LABS's Key Drugs

TEYRO LABS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

TEYRO LABS's Recent FDA Approvals

New NDA/BLA approvals for TEYRO LABS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

TEYRO LABS's Therapeutic Areas

TEYRO LABS's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Gastroenterology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 50%
1 drugs
Gastroenterology 50%
1 drugs

TEYRO LABS's Top Competitors

TEYRO LABS's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

TEYRO LABS Pipeline Snapshot

Active clinical trials for TEYRO LABS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Oncology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling